PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12914384-6 2003 XRCC1 (X-ray cross-complementing group 1), ERCC1 (excision cross-complementing gene) and GSTP1 (glutathione S-transferase) have a role in the development of pharmacoresistance to platinum derivatives. Platinum 179-187 glutathione S-transferase kappa 1 Homo sapiens 96-121 22025407-2 2011 Ethacrynic acid (EA) is able to inhibit the detoxifying enzyme glutathione-S-transferase (GST), which catalyzes the conjugation between GSH and Pt-based drugs. Platinum 144-146 glutathione S-transferase kappa 1 Homo sapiens 63-88 22025407-2 2011 Ethacrynic acid (EA) is able to inhibit the detoxifying enzyme glutathione-S-transferase (GST), which catalyzes the conjugation between GSH and Pt-based drugs. Platinum 144-146 glutathione S-transferase kappa 1 Homo sapiens 90-93 17465714-3 2007 The most recent update regarding gastric cancer pharmacogenetics highlights a prominent role of genetic polymorphisms of thymidylate synthase and glutathione S-transferase in the pharmacological treatment with commonly used drugs, such as 5-fluorouracil and platinum derivatives. Platinum 258-266 glutathione S-transferase kappa 1 Homo sapiens 146-171 16690105-10 2006 In this in vitro study, we determined the downregulation of intracellular GST activity and GSH concentration were the predominant mechanisms involved in the modulation of platinum resistance. Platinum 171-179 glutathione S-transferase kappa 1 Homo sapiens 74-77 28834763-5 2017 In vitro and in vivo results provide strong evidence that GSTs inhibitor-modified cisplatin prodrug combined with nanoparticle encapsulation favor high effective platinum accumulation, significantly enhanced antitumor efficacy against cisplatin-resistant cancer and decreased system toxicity. Platinum 162-170 glutathione S-transferase kappa 1 Homo sapiens 58-62 9679554-1 1998 We examined the correlation between response to platinum-based chemotherapy and expression of glutathione S-transferase (GST), gamma-GGT (both by immunohistochemistry) and gamma-GCS (by in situ hybridization) in 51 patients with head and neck cancer, who received a total of 56 courses of chemotherapy. Platinum 48-56 glutathione S-transferase kappa 1 Homo sapiens 94-119 9679554-1 1998 We examined the correlation between response to platinum-based chemotherapy and expression of glutathione S-transferase (GST), gamma-GGT (both by immunohistochemistry) and gamma-GCS (by in situ hybridization) in 51 patients with head and neck cancer, who received a total of 56 courses of chemotherapy. Platinum 48-56 glutathione S-transferase kappa 1 Homo sapiens 121-124 9679554-8 1998 We conclude that GST expression correlates well with response to platinum based chemotherapy in head and neck cancer. Platinum 65-73 glutathione S-transferase kappa 1 Homo sapiens 17-20 1419639-4 1992 GST isoenzyme patterns were identical in benign tumours and malignant tumours before and after platinum/cyclophosphamide chemotherapy, while GST pi was the predominant transferase. Platinum 95-103 glutathione S-transferase kappa 1 Homo sapiens 0-3 1419639-5 1992 Mean GST activity and GST pi amount were decreased (P < 0.05) in malignant ovarian tumours after platinum/cyclophosphamide chemotherapy compared to untreated ovarian malignant tumours. Platinum 100-108 glutathione S-transferase kappa 1 Homo sapiens 5-8 1419639-5 1992 Mean GST activity and GST pi amount were decreased (P < 0.05) in malignant ovarian tumours after platinum/cyclophosphamide chemotherapy compared to untreated ovarian malignant tumours. Platinum 100-108 glutathione S-transferase kappa 1 Homo sapiens 22-25 30854066-1 2019 Glutathione S-transferase (GST) exhibits antidotal effects on numerous drugs, including platinum-based antineoplastic drugs. Platinum 88-96 glutathione S-transferase kappa 1 Homo sapiens 0-25 30854066-1 2019 Glutathione S-transferase (GST) exhibits antidotal effects on numerous drugs, including platinum-based antineoplastic drugs. Platinum 88-96 glutathione S-transferase kappa 1 Homo sapiens 27-30 12851839-0 2003 Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Platinum 0-8 glutathione S-transferase kappa 1 Homo sapiens 70-95 9816141-0 1996 Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Platinum 80-88 glutathione S-transferase kappa 1 Homo sapiens 33-58 9816141-3 1996 We examined the correlation between expression of GSTs determined by immunohistochemistry and clinical response to platinum-based chemotherapy in 51 patients with head and neck cancer, who received a total of 56 courses of chemotherapy. Platinum 115-123 glutathione S-transferase kappa 1 Homo sapiens 50-54 8898974-2 1996 On the basis of this interaction with both endogenous and synthetic substances, glutathione and the key enzyme for its conjugation, glutathione S-transferase, appear to be critical determinants in tumor cell resistance to several antineoplastic drugs, e.g. platinum analogs. Platinum 257-265 glutathione S-transferase kappa 1 Homo sapiens 132-157 1892748-0 1991 The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Platinum 85-93 glutathione S-transferase kappa 1 Homo sapiens 39-64 34780261-1 2021 BACKGROUND: Genetic polymorphism within the P1 isoenzyme of the Glutathione-S-Transferase (GST) family is found to modulate and alter the enzyme activity of GSTP1 protein and thus may result in a change of sensitivity to platinum-based chemotherapy. Platinum 221-229 glutathione S-transferase kappa 1 Homo sapiens 64-89 34780261-1 2021 BACKGROUND: Genetic polymorphism within the P1 isoenzyme of the Glutathione-S-Transferase (GST) family is found to modulate and alter the enzyme activity of GSTP1 protein and thus may result in a change of sensitivity to platinum-based chemotherapy. Platinum 221-229 glutathione S-transferase kappa 1 Homo sapiens 91-94 26803611-0 2016 Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile. Platinum 74-82 glutathione S-transferase kappa 1 Homo sapiens 121-124 26803611-2 2016 This heterogeneous response might result from inter-individual variations in the platinum-detoxification pathway due to the expression of glutathione-S-transferase (GST) enzymes. Platinum 81-89 glutathione S-transferase kappa 1 Homo sapiens 138-163 26803611-2 2016 This heterogeneous response might result from inter-individual variations in the platinum-detoxification pathway due to the expression of glutathione-S-transferase (GST) enzymes. Platinum 81-89 glutathione S-transferase kappa 1 Homo sapiens 165-168 27073511-1 2016 The effects of platinum-based drugs are controlled by genes that are involved in DNA detoxification, including glutathione S-transferase (GST)P1 and GSTM1, which have been associated with increased benefits in the chemotherapeutic treatment of patients with ovarian cancer. Platinum 15-23 glutathione S-transferase kappa 1 Homo sapiens 111-136